Friday, 23 August 2013

The drug delivery method plays a crucial part in the success of any drug. Drugs with high efficacy and those which are easy to use are an instant success in most medical communities and even among patients. Pulmonary drug delivery is the inhalation of aerosol based drugs through a device called “Inhaler” and the drug aerosol is called an inhalable. 

There are several conventional inhalable drugs particularly for chronic conditions such as asthma, chronic obstructive pulmonary diseases (COPD) and congestion. Conventional methods used pulmonary drug delivery only for respiratory diseases. Today other chronic conditions such as diabetes also have inhaled insulin and provide greater patient comfort compared to insulin injections. Pulmonary drug delivery can be both oral and nasal.

The market for pulmonary drug delivery systems is predicted to grow with advancing technology such as automated pulmonary delivery testing systems. Increasing disease applications and innovative designs for devices will account for significant growth of this market. Faster delivery, greater absorbing surface area of tissue, and greater patient comfort are some of the drivers for pulmonary delivery of drugs. Even with these drivers, the market is not without its challenges. 

Research studies show that some people have lower absorption compared to others and thus the dosage has to be adjusted from one person to another making it difficult for physicians to standardize dosage for all people. Different formulations will also be provided a suitable platform for the delivery of other inhaled protein therapeutics besides insulin. Dry powder inhalers (DPIs) are still expected to have technical hurdles till the next few years.

Geographically the market can be focused world-wide and with increasing applications such as insulin, the market is projected to expand rapidly, particularly in Africa and Asia with large percentage of diabetic population. Currently North America and Europe lead the way in  the market respectively, yet the situation is expected to change in another five years. Insulin inhalers were recently approved in Europe and US, and the market is expected to present sizable opportunities in other regions around the world.

More reports on Pharmaceutical market:

This research report analyzes this market depending on its market segments, major geographies, and current market trends. 

Geographies analyzed under this research report include 
  • North America 
  • Asia Pacific 
  • Europe
  • Rest of the World  
This report provides comprehensive analysis of 
  • Market growth drivers 
  • Factors limiting market growth
  • Current market trends 
  • Market structure
  • Market projections for upcoming years 
This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

About Us:

Transparency Market Research (TMR) is a market intelligence company providing global business research reports and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers.

TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources along with various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information which is indispensable for businesses to sustain their competitive edge.

Contact Us:

State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States

Tel: +1-518-618-1030


Post a Comment